Aaron Urquhart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aaron Urquhart has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Billy Chaplin
Kidney Disease Research Collaborative, Princess Alexandra Hospital and The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia
2 shared publications - Brett Berezowski
Kidney Disease Research Collaborative, Princess Alexandra Hospital and The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia
2 shared publications - David A. Vesey
Kidney Disease Research Collaborative, Princess Alexandra Hospital and The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia
2 shared publications - Glenda Carolyn Gobe
Kidney Disease Research Collaborative, Princess Alexandra Hospital and The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia
2 shared publications - Hemamali Samaratunga
Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, QLD 4102, Australia
2 shared publications - Keng Lim Ng
Kidney Disease Research Collaborative, Princess Alexandra Hospital and The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia
2 shared publications
Latest Publications
- Open Access
Correction: Berezowski et al. Biomarkers in Renal Cell Carcinoma: A Systematic Review and Immunohistochemical Validation Study. Cancers 2025, 17, 2588
There was an error in the original publication
Open AccessCorrection: Berezowski et al. Biomarkers in Renal Cell Carcinoma: A Systematic Review and Immunohistochemical Validation Study. Cancers 2025, 17, 2588
There was an error in the original publication
- Open Access
Biomarkers in Renal Cell Carcinoma: A Systematic Review and Immunohistochemical Validation Study
Background and Objectives: The worldwide incidence of renal cell carcinoma (RCC) rose by 22% between 2012 and 2022. In Australia, RCC accounted for 2.8% of all cancer diagnoses and contributing to 1.8% of cancer-related deaths. Identification of RCC biomarkers may aid in diagnosis and management. Methods: A systematic review of immunohistochemical markers of RCC studies published between 1990 and 2019 was undertaken to select candidate biomarkers of RCC. Immunohistochemical staining of 73 clear cell RCC tumors and paired normal tissue was undertaken using selected markers. Semi-quantitative and quantitative analysis of staining intensity between paired samples was undertaken to evaluate utility as potential biomarkers, using Chi-square tests and paired t-tests for analysis. As an exploratory analysis, staining intensity was also compared on clinical/demographic variables using linear and logistic regression. Results: There were 123 candidate biomarkers identified in 91 studies. Four candidate markers were selected for further investigation: aminopeptidase A (APA)/cluster of differentiation (CD)249, aminopeptidase N (APN)/CD13, gamma-glutamyl transferase (GGT), and neuron-specific enolase (NSE). APA, GGT, and APN all demonstrated reduced staining intensity in the tumor compared with normal tissue (p < 0.001 for all). NSE demonstrated a statistically significant increase in expression in tumor compared with normal tissue (p < 0.001), and this was more pronounced in patients aged >60 years (p = 0.038). Conclusions: The utility of APA, APN, and GGT as diagnostic biomarkers in clear cell RCC is limited. NSE may have some role as a biomarker for clear cell RCC, particularly among older patients; however, further investigation is required.
Open AccessBiomarkers in Renal Cell Carcinoma: A Systematic Review and Immunohistochemical Validation Study
Background and Objectives: The worldwide incidence of renal cell carcinoma (RCC) rose by 22% between 2012 and 2022. In Australia, RCC accounted for 2.8% of all cancer diagnoses and contributing to 1.8% of cancer-related deaths. Identification of RCC biomarkers may aid in diagnosis and management. Methods: A systematic review of immunohistochemical markers of RCC studies published between 1990 and 2019 was undertaken to select candidate biomarkers of RCC. Immunohistochemical staining of 73 clear cell RCC tumors and paired normal tissue was undertaken using selected markers. Semi-quantitative and quantitative analysis of staining intensity between paired samples was undertaken to evaluate utility as potential biomarkers, using Chi-square tests and paired t-tests for analysis. As an exploratory analysis, staining intensity was also compared on clinical/demographic variables using linear and logistic regression. Results: There were 123 candidate biomarkers identified in 91 studies. Four candidate markers were selected for further investigation: aminopeptidase A (APA)/cluster of differentiation (CD)249, aminopeptidase N (APN)/CD13, gamma-glutamyl transferase (GGT), and neuron-specific enolase (NSE). APA, GGT, and APN all demonstrated reduced staining intensity in the tumor compared with normal tissue (p < 0.001 for all). NSE demonstrated a statistically significant increase in expression in tumor compared with normal tissue (p < 0.001), and this was more pronounced in patients aged >60 years (p = 0.038). Conclusions: The utility of APA, APN, and GGT as diagnostic biomarkers in clear cell RCC is limited. NSE may have some role as a biomarker for clear cell RCC, particularly among older patients; however, further investigation is required.